Edition:
United Kingdom

Biomarin Pharmaceutical Inc (BMRN.OQ)

BMRN.OQ on NASDAQ Stock Exchange Global Select Market

82.99USD
22 Nov 2017
Change (% chg)

-- (--)
Prev Close
$82.99
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
449,693
52-wk High
$100.50
52-wk Low
$79.51

Chart for

About

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products... (more)

Overall

Beta: 1.80
Market Cap(Mil.): $16,617.19
Shares Outstanding(Mil.): 175.27
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.15 16.44
EPS (TTM): -- -- --
ROI: -- 14.99 10.62
ROE: -- 16.33 14.20

BRIEF-Biomarin reports Q3 loss $0.07/shr

* Q3 earnings per share view $-0.14 -- Thomson Reuters I/B/E/S

26 Oct 2017

BRIEF-FDA grants Breakthrough Therapy Designation for BioMarin's gene therapy for hemophilia A

* FDA grants Breakthrough Therapy Designation for BioMarin's valoctocogene roxaparvovec (formerly BMN 270), an investigational gene therapy for hemophilia A

26 Oct 2017

BRIEF-Biomarin Pharmaceutical: Increased board size from nine to ten members​

* Biomarin Pharmaceutical says ‍on September 28, 2017, board of directors of increased size of board from nine to ten members​ - SEC filing Source: (http://bit.ly/2yWOHiP) Further company coverage:

03 Oct 2017

BRIEF-FDA not planning to hold advisory committee meeting for Biomarin's Pegvaliase BLA

* FDA not currently planning to hold advisory committee meeting for Biomarin's Pegvaliase Biologics License Application (BLA)

14 Sep 2017

BRIEF-FDA accepts Biomarin's Pegvaliase Biologics License Application

* FDA accepts Biomarin's Pegvaliase Biologics License Application (bla) and grants priority review designation

29 Aug 2017

BRIEF-BioMarin announces offering of $450 mln of 0.599 pct senior convertible notes

* BioMarin announces offering of $450 million of 0.599% senior subordinated convertible notes due 2024

08 Aug 2017

BRIEF-Biomarin announces offering of $450 mln of senior subordinated convertible notes due 2024

* Biomarin announces offering of $450 million of senior subordinated convertible notes due 2024

07 Aug 2017

BRIEF-BioMarin announces plans to progress both the 6e13vg/kg and 4e13 vg/kg doses of BMN 270, its investigational gene therapy for Hemophilia A, into phase 3 studies

* BioMarin announces plans to progress both the 6e13vg/kg and 4e13 vg/kg doses of BMN 270, its investigational Gene Therapy For Hemophilia A, into phase 3 studies

02 Aug 2017

BRIEF-Sarepta and Biomarin report execution of global settlement

* Sarepta Therapeutics and Biomarin Pharmaceutical Inc. Announce execution of a global settlement and a license agreement resolving exon skipping patent litigation

18 Jul 2017

BRIEF-Biomarin Pharmaceutical says plans to initiate phase 3 registrational study in Q4 2017 for BMN 270

* Biomarin's Investigational Gene Therapy for Hemophilia A at 6e13 vg/kg dose maintains average factor VIII levels within normal range for over one year

11 Jul 2017

Competitors

Earnings vs. Estimates